Author:
Shah Manish A.,Power Derek G.,Kindler Hedy L.,Holen Kyle D.,Kemeny Margaret M.,Ilson David H.,Tang Laura,Capanu Marinela,Wright John J.,Kelsen David P.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference39 articles.
1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108
2. Van Cutsem E, Kang K, Chung H et al (2009) Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). American Society of Clinial Oncology, Annual Proceedings, Orlando, FL, USA. May 29th–June 2nd; Abstract #LBA 4509
3. Bang Y, Chung H, Xu J et al (2009) Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. Amercan Society of Clinical Oncology, Annual Proceedings, Orlando, FL, 29 May–2 June 2009; Abstract #4556
4. Glickman MH, Ciechanover A (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82:373–428
5. Lenz HJ (2003) Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev 29(Suppl 1):41–48
Cited by
39 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献